Tabuk Pharma has entered into a strategic partnership with Althera Laboratories to introduce an innovative treatment for type 2 diabetes across the MENA region. This collaboration reinforces Tabuk Pharma’s commitment to expanding value-added therapeutic solutions and enhancing healthcare quality, in alignment…
Tabuk Pharma Signs Strategic Agreements with Local Content and Government Procurement Authority at Global Health Exhibition 2025
As part of the Global Health Exhibition 2025, Tabuk Pharma signed two strategic agreements with the Local Content and Government Procurement Authority, marking a significant milestone in strengthening pharmaceutical localization and advancing the Kingdom’s healthcare capabilities. These agreements reflect a shared…
Tabuk Pharma Signs Exclusive License and Supply Agreement with Hanmi Pharmaceutical for Rolontis® (Eflapegrastim) in Saudi Arabia and MENA
Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis® (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Arabia and the MENA region. This strategic collaboration underscores Tabuk Pharma’s commitment to expanding…